Clinical Senior Lecturer and Honorary Consultant in Thoracic Medical Oncology
0161 446 8125
BSc, MBChB, MRCP, PhD
Started at The Christie (Year)
Treatment of non-small cell lung cancer and small cell lung cancer. NHS clinics and ward rounds, principal and co-investigator for phase II and phase III clinical trials, multi-disciplinary meetings for Greater Manchester central sector.
Outside of seeing patients, my time is dedicated to cancer research for the University of Manchester, working closely with the Cancer Research UK Manchester Institute and CRUK at the Crick Institute in London.
Dr Lindsay was educated at Edinburgh University. He began Medical Oncology training at the Beatson West of Scotland Cancer Centre in 2006 and was awarded a four-year Medical Research Council Fellowship in 2009 to complete a PhD in the Cancer Research UK Beatson Institute. During this time, he was awarded the Association of Cancer Physicians McElwain Prize, an annual award offered to one UK medical oncology trainee for outstanding contribution to cancer research.
Following completion of his PhD, Dr Lindsay was closely involved with phase I of the Cancer Research UK Stratified Medicine Programme before being sponsored by the European Society for Medical Oncology and the International Association for the Study of Lung Cancer to undertake a translational lung cancer fellowship at Europe’s leading lung cancer centre, the Gustave Roussy Institute in Villejuif, France. He returned to the UK and was appointed as a Clinical Senior Lecturer and Honorary Consultant in Medical Oncology at the Christie in 2017.
Dr Lindsay is currently establishing translational research links in lung cancer in collaboration with Dr Angeliki Malliri (CRUK Manchester Institute) and the Crick Institute in London. Along with his colleagues, he also organises a clinical trials portfolio of more than 80 phase I-III trials, and has been involved in practice-changing studies delivering promising new drugs and treatment regimens to patients.
Dr Lindsay’s overall objective is to implement new developments in lung cancer treatment, biomarkers or genetic tests through effective clinical trial delivery.
Lung Cancer, clinical trials, small molecule inhibitors, immunotherapy, circulating biomarkers, KRAS mutation.